Durable response for ampullary and duodenal adenocarcinoma with a nab ‐paclitaxel plus gemcitabine ± cisplatin combination

ConclusionsNab ‐paclitaxel plus gemcitabine with or without cisplatin should be investigated as a standard‐of‐care chemotherapy regimen for patients with ampullary adenocarcinoma and duodenal adenocarcinoma.

Source: Cancer Medicine - May 16, 2019 Category: Cancer & Oncology Authors: Putao Cen, Curtis J. Wray, Songlin Zhang, Nirav C. Thosani, Brian Cuong Dinh, Anneliese Gonzalez, Virginia Mohlere, John Steven Bynon Tags: ORIGINAL RESEARCH Source Type: research